Final answer:
The pharmacist in the cardiac ICU should alert the medical team about interactions between cardiac medications, notably beta blockers, considering both pharmacokinetic and pharmacodynamic risks, as well as individual pharmacogenomic factors.
Step-by-step explanation:
The pharmacist in a cardiac ICU medical team plays a crucial role in monitoring for potential drug interactions to ensure patient safety. They should be particularly vigilant about interactions involving cardiac medications such as beta blockers, calcium channel blockers, anticoagulants like warfarin (Coumadin), rivaroxaban (Xarelto), and antibiotics prevalent in ICU settings such as aminoglycosides (e.g., gentamicin, streptomycin, tobramycin), macrolides (e.g., azithromycin, clarithromycin, erythromycin), and tetracyclines.
The pharmacist should also be aware of pharmacogenomic factors that can affect individual responses to drugs like warfarin, as variations in liver function can impact drug metabolism and increase the risk of overdose or subtherapeutic effects.